Literature DB >> 21232712

Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment.

Marvin A Konstam1, Daniel G Kramer, Ayan R Patel, Martin S Maron, James E Udelson.   

Abstract

Ventricular remodeling, first described in animal models of left ventricular (LV) stress and injury, occurs progressively in untreated patients after large myocardial infarction and in those with dilated forms of cardiomyopathy. The gross pathologic changes of increased LV volume and perturbation in the normal elliptical LV chamber configuration is driven, on a histologic level, by myocyte hypertrophy and apoptosis and by increased interstitial collagen. Each of the techniques used for tracking this process-echocardiography, radionuclide ventriculography, and cardiac magnetic resonance-carries advantages and disadvantages. Numerous investigations have demonstrated the value of LV volume measurement at a single time-point and over time in predicting clinical outcomes in patients with heart failure and in those after myocardial infarction. The structural pattern of LV remodeling and evidence of scarring on cardiac magnetic resonance have additional prognostic value. Beyond the impact of abnormal cardiac structure on cardiovascular events, the relationship between LV remodeling and clinical outcomes is likely linked through common local and systemic factors driving vascular as well as myocardial pathology. As demonstrated by a recent meta-analysis of heart failure trials, LV volume stands out among surrogate markers as strongly correlating with the impact of a particular drug or device therapy on patient survival. These findings substantiate the importance of ventricular remodeling as central in the pathophysiology of advancing heart failure and support the role of measures of LV remodeling in the clinical investigation of novel heart failure treatments. 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21232712     DOI: 10.1016/j.jcmg.2010.10.008

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  220 in total

Review 1.  Cardiac remodeling at the population level--risk factors, screening, and outcomes.

Authors:  Ola Gjesdal; David A Bluemke; Joao A Lima
Journal:  Nat Rev Cardiol       Date:  2011-10-25       Impact factor: 32.419

2.  Chronic social stress induces cardiomyocyte contractile dysfunction and intracellular Ca2+ derangement in rats.

Authors:  Subat Turdi; Ming Yuan; Gail M Leedy; Zhenbiao Wu; Jun Ren
Journal:  Physiol Behav       Date:  2011-09-17

Review 3.  Cardiovascular implications of idiopathic pulmonary fibrosis: A way forward together?

Authors:  Christopher L Mosher; Robert J Mentz
Journal:  Am Heart J       Date:  2020-05-06       Impact factor: 4.749

Review 4.  Injectable Hydrogels for Cardiac Tissue Engineering.

Authors:  Brisa Peña; Melissa Laughter; Susan Jett; Teisha J Rowland; Matthew R G Taylor; Luisa Mestroni; Daewon Park
Journal:  Macromol Biosci       Date:  2018-05-07       Impact factor: 4.979

5.  Cardiac magnetic resonance-tissue tracking for the early prediction of adverse left ventricular remodeling after ST-segment elevation myocardial infarction.

Authors:  Min Jae Cha; Jeong Hyun Lee; Hye Na Jung; Yiseul Kim; Yeon Hyeon Choe; Sung Mok Kim
Journal:  Int J Cardiovasc Imaging       Date:  2019-07-03       Impact factor: 2.357

6.  Influence of baseline left ventricular function on the clinical outcome of surgical ventricular reconstruction in patients with ischaemic cardiomyopathy.

Authors:  Jae K Oh; Eric J Velazquez; Lorenzo Menicanti; Gerald M Pohost; Robert O Bonow; Grace Lin; Anne S Hellkamp; Paolo Ferrazzi; Stanislaw Wos; Vivek Rao; Daniel Berman; Andrzej Bochenek; Alexander Cherniavsky; Jan Rogowski; Jean L Rouleau; Kerry L Lee
Journal:  Eur Heart J       Date:  2012-05-14       Impact factor: 29.983

7.  Image-based left ventricular shape analysis for sudden cardiac death risk stratification.

Authors:  Fijoy Vadakkumpadan; Natalia Trayanova; Katherine C Wu
Journal:  Heart Rhythm       Date:  2014-05-20       Impact factor: 6.343

8.  BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure.

Authors:  Qiming Duan; Sarah McMahon; Priti Anand; Hirsh Shah; Sean Thomas; Hazel T Salunga; Yu Huang; Rongli Zhang; Aarathi Sahadevan; Madeleine E Lemieux; Jonathan D Brown; Deepak Srivastava; James E Bradner; Timothy A McKinsey; Saptarsi M Haldar
Journal:  Sci Transl Med       Date:  2017-05-17       Impact factor: 17.956

9.  Targeted Injection of a Truncated Form of Tissue Inhibitor of Metalloproteinase 3 Alters Post-Myocardial Infarction Remodeling.

Authors:  David C Lobb; Heather Doviak; Gregory L Brower; Eva Romito; Jason W O'Neill; Stephen Smith; James A Shuman; Parker D Freels; Kia N Zellars; Lisa A Freeburg; Aarif Y Khakoo; TaeWeon Lee; Francis G Spinale
Journal:  J Pharmacol Exp Ther       Date:  2020-09-21       Impact factor: 4.030

10.  Plasma galectin 3 and heart failure risk in the Physicians' Health Study.

Authors:  Luc Djoussé; Chisa Matsumoto; Andrew Petrone; Natalie L Weir; Michael Y Tsai; J Michael Gaziano
Journal:  Eur J Heart Fail       Date:  2013-12-04       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.